Information about Lagevrio (Molnupiravir)
Lagevrio, also known as Molnupiravir, is an antiviral medication designed to treat COVID-19. It works by introducing errors into the viral RNA during replication, which helps to inhibit the virus's ability to multiply and spread.
Product Highlights
- Indicated for mild to moderate COVID-19 in adults at high risk of progressing to severe disease.
Key Ingredient
Key Benefits
- Aims to lower the likelihood of severe illness and hospitalization.
- Oral formulation allows for easy and timely treatment initiation.
- Specifically designed to inhibit RNA viruses, potentially reducing viral load.
Direction of Use
- Typically, the recommended dose is 800 mg taken every 12 hours for 5 days, initiated as soon as possible after diagnosis and within 5 days of symptom onset.
- Swallow capsules whole with or without food.
Safety Concerns
- May include nausea, diarrhea, and headaches. Monitoring for serious adverse reactions is advised.
- Not recommended for use during pregnancy; contraception should be used during treatment.
Avoid Lagevrio (Molnupiravir) If
- You are pregnant or breastfeeding.
- You have a known hypersensitivity to Molnupiravir or any component of the formulation.
- You are currently taking medications that may interact negatively with Molnupiravir.
